

## **ANNUAL GENERAL MEETING MINUTES OF THE MEDICAL TECHNOLOGY ASSOCIATION OF NZ**

3:30pm, 25 June 2024

---

### **MINUTES OF THE 2023 AGM**

Minutes were circulated prior to the meeting and were taken as a true and correct record of the meeting. There were no matters arising from last minutes.

**Approved:** *Andrew Short, Permobil*

**Seconded:** *Anthony Blythe, Arjo*

### **ELECTION OF EXECUTIVE BOARD**

Note that the election of the executive board was brought forward in the agenda to allow the maximum number of members to vote.

#### **2023 Board members:**

- Erin Currie, Philips
- Andrew Hickey, Intermed
- Chris Iles, Obex
- Sarah Najdek, Johnson & Johnson Medtech stood down in December 2023 and Amy Wilkinson was seconded
- Anne Familton, Becton Dickinson
- John Matthews, EBOS Healthcare
- Wing Lam Wong, Roche Diagnostics

The following nominees stood for election.

#### **Nominations:**

The following existing board members sought re-election:

- Erin Currie, Country Manager, Health Systems, Philips (Currently Deputy Chair)
- John Matthews, NZ Manager, EBOS Healthcare
- Amy Wilkinson, GM and Country Director at J&J MedTech (Seconded)

Additionally, three new nominees stood:

- Kate King, Director of Government Affairs, Medtronic, ANZ
- Polo Guilbert-Wright, Senior Director Government Affairs, ANZ
- Yariv Levin, Chief Compliance Officer, Toku Eyes

The membership voted with the following result.

### **Election Result**

- Erin Currie, Country Manager, Health Systems, Philips (Currently Deputy Chair)
- Kate King, Director of Government Affairs, Medtronic, ANZ
- Amy Wilkinson, GM and Country Director at J&J MedTech (Seconded)

Andrew Hickey moved that the voting papers be destroyed.

**Approved:** *Pieter Wijnhoud, Obex*

**Seconded:** *Chandra Selvadurai, Pharmaco*

### **PRESIDENTS REPORT**

Andrew Hickey presented the following report:

A sentiment that would have rung true at any time in the past half-dozen years or so, but one that is particularly relevant to the past 12 months. A change of government, new health ministers, the passing of a new regulatory regime, the subsequent plan to repeal that same legislation, ongoing uncertainty around division of responsibility between stakeholders in the health sector, internal staff changes, new board members, and a new chair. It has been a period that has tested MTANZ as an organisation, challenging us to be agile and adapt to what seemed to be an endless stream of new information to digest and respond to. That being said, I am filled with a great sense of pride to say that not only have we survived, but we have thrived during this period of evolution. I firmly believe we have provided significant value to our most important stakeholders – our members – during this period.

A little over a year ago, we were in the midst of a public consultation process regarding the Therapeutic Products Bill (as it was known at the time). This bill went on to be passed through parliament by the previous Labour Government in July 2023. Renamed the Therapeutic Products Act (TPA) after passing through the parliamentary process, it was set to change the regulatory regime for medical devices in New Zealand, ultimately significantly impacting the future operating environment of our industry and for all members. Advocating on behalf of the industry regarding this piece of legislation and the Rules and Regulations that were to follow would have dominated much of MTANZ's focus for the foreseeable future.

Fast forward to May 2024, and with the new coalition government in place, a government which promises to be more consultative and to listen more carefully to industry, we have been provided somewhat of a 'second chance' regarding regulatory reform in New Zealand, given the government's stated policy of repealing the TPA. While we welcome this as a positive for MTANZ and our members, the ongoing stakeholder engagement and consultation process around what a 'future state of medical device regulation for New Zealand' will be remains unclear at this stage. It is great that the government has delivered on its promise to repeal the TPA, but it also inevitably leads to uncertainty around what will replace it in due course. Much of MTANZ's focus for the foreseeable future will be on ensuring that our voice is heard, and we have a seat at the table as any new regulatory legislation is being developed. As part of our response to the ongoing work related to regulatory reform, MTANZ introduced a new Special Advisory Group in the past year, the Regulatory Affairs Group (or the RAG), to help build our capacity and capability to engage with relevant stakeholders on this critical matter.

While we should acknowledge the win regarding the repeal of the TPA, the battle to ensure a 'Fit for Purpose' regulatory regime for medical devices in New Zealand is not over. With the RAG now established, MTANZ is better positioned than ever before to respond to and inform future policy direction around medical device regulation.

Our other Special Advisory Groups – the Government Affairs and Policy (GAP) and the Market Access Group (MAG) - have continued to deliver on their agreed workplans. Given the rapid changes in the political environment over the past 12 months, the GAP has proven to be an invaluable resource and advisor for Cushla and her team, as well as the board. The MAG continue to advocate for clear 'Rules of Engagement' with organisations such as Te Whatu Ora / Health New Zealand and Pharmac, as these organisations' remits continue to evolve. Looking forward, both the GAP and the MAG have clearly stated strategic objectives that align with the boarder organisational plan and significant workstreams ahead as the new government rolls out its vision for the health sector. I am confident that with the technical expertise in each of the three Special Advisory Groups, building off groundwork already in place, and continued strong member engagement, we are well-positioned to deliver on our strategic plan.

The last year has also been a very busy one for the team at MTANZ, delivering on a very successful Healthtech Week in June 2023 and our first Dental Expo since before COVID. These two major events, along with several other exhibitions throughout the year, culminated in a very strong financial result for FY24. It is a credit to the MTANZ team that these financial results were delivered despite some staff turnover and changes to our underlying operating structure during the year.

As we enter FY25, there are significant objectives to achieve and challenges to overcome. However, we have already established good working relationships with the new government, we are engaged with the right stakeholders at Pharmac and Health New Zealand, and I believe we should be optimistic about the year ahead. It is worth noting that from a governance perspective, over the next year, the board will be looking to finalise an update to the MTANZ constitution in order to bring us in line with the requirements of the updated Incorporated Societies Act. You will hear more about this in due course, and will require approval of the membership at a General Meeting, likely the next AGM if not before.

In closing, I would like to acknowledge and thank some individuals. To all of the members of the Special Advisory Groups, thank you for your expertise and for being so giving of your time. To my fellow board members, - thank you once again for your ongoing support and wise counsel. And last but certainly not least, I want to specifically acknowledge and thank Cushla Symth, who has been the driving force of the MTANZ organisation.

**Approved:** Andrew Short, Permobil

**Seconded:** Alex Bamford, Bamford

## **CHIEF EXECUTIVE OFFICER'S REPORT**

Cushla Smyth presented the slide deck in Appendix One.

**Accepted:** Katie Noble, Allied Medical

**Seconded:** Kate King, Medtronic

## **FINANCIAL REPORT**

Chris Isles presented the Annual Accounts for 2022-2023

- Surplus: \$147,640, Budget \$59,660, LY (\$44,949)
- Operating income – 22% above Budget
- Gross profit – 8% above Budget
- Operating expenses – 0% against Budget
- Net Assets: \$602k, 32% increase over 2023
  
- Budget FY25: \$59k deficit.
- Clean audit report
- Reporting changes

**Approved:** Anthony Blythe, Arjo

**Seconded:** Kate King, Medtronic

## **INCORPORATED SOCIETIES ACT CHANGES**

Andrew Hickey presented the slide deck in Appendix Two to highlight the changes to the legislation detailing timing and new responsibilities for board members.

## **GENERAL BUSINESS**

- It was raised that changes to management at Health NZ may make engagement for industry more difficult and therefore MTANZ should have a plan to mitigate this.

**5.00pm AGM closed**